药物类型 通用型CAR-T |
别名 Anti-CD7 Allogeneic CAR-T Cells(Wugen) + [2] |
靶点 |
作用机制 CD7调节剂(T细胞抗原CD7调节剂) |
非在研适应症- |
原研机构 |
非在研机构- |
最高研发阶段临床2期 |
首次获批日期- |
最高研发阶段(中国)临床1/2期 |
特殊审评优先药物(PRIME) (欧盟)、罕见儿科疾病 (美国)、快速通道 (美国)、孤儿药 (美国)、再生医学先进疗法 (美国) |
开始日期2024-12-13 |
申办/合作机构 |
开始日期2023-10-10 |
申办/合作机构 |
开始日期2023-06-26 |
申办/合作机构 |
Relapsed/refractory T-cell acute lymphoblastic leukemia (ALL)/lymphoma (LBL) represent a significant unmet medical need. WU-CART-007 is a CD7-targeting, allogeneic, fratricide-resistant chimeric antigen receptor T cell product generated from healthy donor T cells. WU-CART-007 was evaluated in a phase 1/2 study with a 3 + 3 dose-escalation design followed by cohort expansion in relapsed/refractory T-ALL/LBL. Patients received one infusion of WU-CART-007 after standard or enhanced lymphodepleting chemotherapy. The primary objectives, to characterize safety and assess the composite complete remission rate, were met. Of 26 patients enrolled, 13 received the recommended phase 2 dose (RP2D) of 900 million cells of WU-CART-007 with enhanced lymphodepletion. The most common treatment-related adverse event was cytokine release syndrome (88.5%; 19.2% grade 3–4). Biochemical abnormalities consistent with grade 2 hemophagocytic lymphohistiocytosis were seen in one patient (3.8%). Grade 1 immune effector cell-associated neurotoxicity syndrome events (7.7%) and one grade 2 acute graft-vs-host disease event occurred. Grade 5 events (11.5%) were due to fungal infection and multi-organ failure. The composite complete remission rate was 81.8% among 11/13 patients evaluable for response at the RP2D. WU-CART-007 at the RP2D demonstrated a high response rate in patients with relapsed/refractory T-ALL/LBL and has the potential to provide a new treatment option. ClinicalTrials.gov registration: NCT04984356.
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
难治性 T 急性淋巴细胞白血病 | 临床2期 | 中国 | 2024-03-29 | |
淋巴母细胞淋巴瘤 | 临床2期 | 法国 | 2022-01-14 | |
淋巴母细胞淋巴瘤 | 临床2期 | 美国 | 2022-01-14 | |
淋巴母细胞淋巴瘤 | 临床2期 | 澳大利亚 | 2022-01-14 | |
淋巴母细胞淋巴瘤 | 临床2期 | 荷兰 | 2022-01-14 | |
T细胞急性淋巴细胞白血病/淋巴瘤 | 临床2期 | 荷兰 | 2022-01-14 | |
T细胞急性淋巴细胞白血病/淋巴瘤 | 临床2期 | 澳大利亚 | 2022-01-14 | |
T细胞急性淋巴细胞白血病/淋巴瘤 | 临床2期 | 美国 | 2022-01-14 | |
T细胞急性淋巴细胞白血病/淋巴瘤 | 临床2期 | 法国 | 2022-01-14 |
研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
---|
临床1/2期 | 26 | (RP2D) | (醖願艱壓鹽繭鏇齋遞糧) = 齋齋淵築醖糧窪襯構餘 壓鹹網積齋糧糧齋蓋夢 (窪糧艱夢淵鏇廠鬱淵艱 ) 更多 | 积极 | 2024-08-05 | ||
临床1/2期 | 13 | (憲淵艱糧積壓製觸積餘) = 鏇獵衊積範鏇鏇築願糧 襯糧憲獵糧簾鑰壓醖艱 (選繭夢衊艱製醖獵簾蓋 ) 更多 | 积极 | 2024-05-14 | |||
N/A | - | (願觸構鏇願艱膚願艱憲) = 製膚壓遞醖糧蓋願範淵 鹽築築選膚壓鑰選窪糧 (蓋遞選鬱壓夢廠糧鹹餘 ) 更多 | - | 2024-05-14 | |||
(願觸構鏇願艱膚願艱憲) = 願積積夢壓蓋願構夢壓 鹽築築選膚壓鑰選窪糧 (蓋遞選鬱壓夢廠糧鹹餘 ) 更多 | |||||||
临床1/2期 | 18 | (糧選簾艱鑰壓蓋製襯選) = 積齋簾鹹糧憲獵齋蓋鬱 獵顧艱網鏇夢顧繭糧醖 (鑰構餘糧繭獵餘積廠構 ) 更多 | 积极 | 2023-12-11 |